Propanc Biopharma plans Phase 1b trial of PRP proenzyme therapy in advanced solid tumors in Q4
PPCB•Phase 1b study planned for advanced solid tumors
Propanc Biopharma outlined plans to enter a first-in-human Phase 1b study of PRP in advanced solid-tumor patients, with emphasis on pancreatic cancer.
The company said results have not been presented, and it expects to file the clinical trial application in Q4 2026.
PRP positioned as long-term, non-cytotoxic therapy
PRP is positioned as a non-cytotoxic, long-term therapy intended to slow disease spread and reduce relapse risk by reprogramming malignant cells.
The update highlighted supportive preclinical and compassionate-use observations, framing PRP as a potential backbone or maintenance option alongside existing treatments.
